| Molecular Formula | C82H107N5O20 |
| Molar Mass | 1482.75 |
| Solubility | DMSO: ≥ 57 mg/mL |
| Storage Condition | -20℃ |
| In vitro study | When LNCaP cells are treated with AP20187 (B/B Homodimerizer) (100 nM), ro-iCaspase-9 levels are significantly reduced, and the smaller processed active caspase-9 becomes apparent. |
| In vivo study | Real-time PCR analysis shows that AP20187 (B/B Homodimerizer) (0.5 mg/kg, 2 mg/kg, or 5 mg/kg) treatment significantly increases the levels of CHOP mRNA in the CNS of PLP/Fv2E-PERK mice at PID12. AP20187 treatment significantly alleviates EAE-induced myelin damage in these mice. AP20187 (B/B Homodimerizer) treatment significantly reduces the number of degenerating axons and increases the density of axons in the demyelinating lesions in the lumbar spinal cord of PLP/Fv2E-PERK mice. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 0.674 ml | 3.372 ml | 6.744 ml |
| 5 mM | 0.135 ml | 0.674 ml | 1.349 ml |
| 10 mM | 0.067 ml | 0.337 ml | 0.674 ml |
| 5 mM | 0.013 ml | 0.067 ml | 0.135 ml |
| biological activity | AP20187 (B/B Homodimerizer) is a cell-permeable molecule that dimerges FK506 binding protein (FKBP), initiates biological signal transduction cascade and gene expression, or destroys protein-protein interactions. |
| target | FKBP homodimerizer |
| in vitro study | when LNCaP cells are treated with AP20187 (B/B Homodimerizer) (100 nM), ro-iCaspase-9 levels are significantly reduced, and the smaller processed active caspase-9 becomes apparent. |
| in vivo study | Real-time PCR analysis shows that AP20187 (B/B Homodimerizer) (0.5 mg/kg, 2 mg/kg, or 5 mg/kg) treatment significantly increases the levels of CHOP mRNA in the CNS of PLP/Fv2E-PERK mices at PID12. AP20187 treatment significantly alleviates EAE-induced myelin damage in these mices. AP20187 (B/B Homodimerizer) treatment significantly reduces the number of degenerating axons and increases the density of axons in the demyelinating lesions in the lumbar spinal cord of PLP/Fv2E-PERK mices. |